CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Adjuvant therapy for patients with HR+/HER2- EBC at high risk of recurrence (ID 338)

Lecture Time
19:15 - 19:30
Speakers
  • S. Johnston (London, United Kingdom)
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00